Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

The deal centres around TNB-486, a bispecific CD19 and CD3 T-cell engager in phase 1 testing in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (NHL) who have received two or ...

which binds to CD3 and CD19 receptors and was approved by the FDA in 2014 and in the EU a year later. Tarlatamab (formerly AMG 757) is the next in the company’s BiTE pipeline to start regulatory ...

Bargou et al. assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non-Hodgkin lymphoma who relapsed after standard treatments.

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

CDR111, CDR-Life’s newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and CD3, designed to achieve immune reset through broad B cell depletion. This novel therapeutic ...